Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Immunotherapy cocktail targets tough blood cancers

NCT ID NCT01592370

Disease control Sponsor: Bristol-Myers Squibb Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug nivolumab (Opdivo), alone or combined with other drugs, in 320 people with relapsed or refractory non-Hodgkin lymphoma, Hodgkin lymphoma, or multiple myeloma. The main goal was to check safety and side effects, especially for the nivolumab plus daratumumab combination. Researchers also looked at how well the tumors responded. The trial has completed, and results help guide future research.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
nivolumab (Opdivo), alone or combined with ipilimumab, lirilumab, daratumumab, pomalidomide, or dexamethasone
What this could lead to
If successful, this could point toward new treatment options for patients with hard-to-treat blood cancers like lymphoma and multiple myeloma.
What could go wrong
This is an early-phase trial focused on safety, not a proven treatment. Results may not lead to a standard therapy, and side effects can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

320 people

The number who actually took part.

Started

Aug 2012

Finished

Jul 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Have received at least 3 prior lines of therapy, including a proteasome inhibitor \[PI\] and an immunomodulatory agent \[IMiD\] OR have disease that is double refractory to a PI and IMiD * More than 12 weeks post-transplant of your own blood forming stem cells (autologous transplant) * Have detectable disease measured by a specific protein in your blood and/or urine * Must consent to bone marrow aspirate or biopsy. Exclusion Criteria: * Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia, or monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), primary amyloidosis, Waldenstrom's macroglobulinemia, POEMS syndrome or active plasma cell leukemia * Prior therapy with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti CTLA 4, or anti-CD38 antibody, or allogeneic stem cell transplantation * Seropositive for human immunodeficiency virus (HIV), Hepatitis B surface antigen or Hepatitis C antibody positive (except if HCV-RNA negative), or history of active chronic hepatitis B or C * History of central nervous system involvement or symptoms suggestive of central nervous system involvement by multiple myeloma Other protocol defined inclusion/exclusion criteria could apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hodgkin lymphoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hodgkins lymphoma non-Hodgkin lymphoma plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hodgkin lymphoma Multiple myeloma Non-Hodgkin's lymphoma

Contacts and locations

Locations

  • Abramson Cancer Center

    Philadelphia, Pennsylvania, 19104, United States

  • Dana-Farber Cancer Institute

    Boston, Massachusetts, 02215, United States

  • Division Of Hematology & Oncology Ctr. For Health Sciences

    Los Angeles, California, 90095, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Huntsman Cancer Institute At The Univ. Of Utah

    Salt Lake City, Utah, 84112, United States

  • John Theurer Cancer Center

    Hackensack, New Jersey, 07601, United States

  • Local Institution

    Yvoir, B-5530, Belgium

  • Local Institution

    Bologna, 40138, Italy

  • Local Institution

    Chorzów, 41-500, Poland

  • Local Institution - 0001

    New York, New York, 10065, United States

  • Local Institution - 0002

    Rochester, Minnesota, 55905, United States

  • Local Institution - 0003

    Baltimore, Maryland, 21231, United States

  • Local Institution - 0004

    Philadelphia, Pennsylvania, 19111, United States

  • Local Institution - 0005

    Salt Lake City, Utah, 84112, United States

  • Local Institution - 0006

    Portland, Oregon, 97239, United States

  • Local Institution - 0007

    Philadelphia, Pennsylvania, 19104, United States

  • Local Institution - 0009

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0011

    Ann Arbor, Michigan, 48109, United States

  • Local Institution - 0012

    Los Angeles, California, 90095, United States

  • Local Institution - 0014

    Hackensack, New Jersey, 07601, United States

  • Local Institution - 0015

    Boston, Massachusetts, 02215, United States

  • Local Institution - 0017

    Aurora, Colorado, 80045, United States

  • Local Institution - 0018

    Westwood, Kansas, 66205, United States

  • Local Institution - 0019

    Indianapolis, Indiana, 46202, United States

  • Local Institution - 0023

    Orlando, Florida, 32804, United States

  • Local Institution - 0028

    Columbus, Ohio, 43210, United States

  • Local Institution - 0033

    Omaha, Nebraska, 68130, United States

  • Local Institution - 0035

    Clovis, California, 93611, United States

  • Local Institution - 0037

    Skokie, Illinois, 60077, United States

  • Local Institution - 0039

    Athens, 11528, Greece

  • Local Institution - 0040

    Poznan, 61-848, Poland

  • Local Institution - 0042

    Wroclaw, 50-367, Poland

  • Local Institution - 0043

    Poitiers, Vienne, 86021, France

  • Local Institution - 0044

    Nantes, 44000, France

  • Local Institution - 0045

    Ghent, 9000, Belgium

  • Local Institution - 0047

    Sint-Niklaas, 9100, Belgium

  • Local Institution - 0049

    Warsaw, 02-776, Poland

  • Local Institution - 013

    New Haven, Connecticut, 06520, United States

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10065, United States

  • OHSU Center for Hematologic Malignancies

    Portland, Oregon, 97239, United States

  • The Sidney Kimmel Comprehensive Cancer Center

    Baltimore, Maryland, 21231, United States

  • University Of Michigan Health System

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.